Talk:5-MeO-PiPT

This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.

This page has not been fully approved by the PsychonautWiki administrators. It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: 5-MeO-PiPT

5-MeO-PiPT
Chemical Nomenclature
Common names	DMT, Dimethyltryptamine, Dmitri
Substitutive name	N,N-Dimethyltryptamine
Systematic name	2-(1H-Indol-3-yl)-N,N-dimethylethanamine
Class Membership
Psychoactive class	Psychedelic
Chemical class	Tryptamine
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Oral Dosage Bioavailability x% - y% Threshold x - mg Light x - y mg Common x - y mg Strong x - y mg Heavy x mg + Duration Total x - y hours Onset x - y minutes Come up x - y minutes Peak x - y hours Offset x - y hours After effects x - y hours ⇣ Sublingual Dosage Bioavailability x% - y% Threshold x - mg Light x - y mg Common x - y mg Strong x - y mg Heavy x mg + Duration Total a - b hours Onset a - b minutes Come up a - b minutes Peak a - b hours Offset a - b hours After effects a - b hours DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

For tips on how to properly format a substance article, please refer to this document: Content Style Guide - Substance

History and culture

This History and culture section is a stub. As a result, it may contain incomplete or wrong information. You can help by expanding it.

5-MeO-PiPT (also known as Poxy) is a synthetic substituted tryptamine that first appeared as a designer drug. It was identified in drug checking samples in British Columbia, Canada, in 2021. It was not described or tested by Alexander Shulgin and is absent from TiHKAL. Very little information on its recreational use or cultural impact is available due to its relative obscurity. Anecdotal reports say it's a more sedating and calmer version that 5-MeO-MiPT (Moxy) and 5-MeO-DiPT (Foxy) with more visuals.

Chemistry

This chemistry section is incomplete. You can help by adding to it.

5-MeO-PiPT, systematically named N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-(propan-2-yl)propan-1-amine (or 5-methoxy-N-propyl-N-isopropyltryptamine), is a substituted tryptamine and 5-methoxytryptamine. It features a methoxy group at the 5-position of the indole ring and asymmetric N,N-dialkyl substitution (n-propyl and isopropyl) on the ethylamine side chain.

Its molecular formula is C₁₇H₂₆N₂O and its molar mass is 274.408 g·mol⁻¹. It is structurally related to other 5-methoxytryptamines such as 5-MeO-DMT, 5-MeO-MiPT, 5-MeO-DiPT, 5-MeO-EiPT, and 5-MeO-DPT, as well as the unsubstituted parent compound PiPT and the 4-hydroxy analogue 4-HO-PiPT.

CAS Number: 2945111-53-3

Pharmacology

This pharmacology section is incomplete. You can help by adding to it.

5-MeO-PiPT acts as a non-selective serotonin receptor agonist. It is an agonist at the 5-HT_1A and 5-HT_2A receptors, with a reported EC₅₀ of 13.8 nM and efficacy of 89% (receptor subtype assignment for these exact values is not fully detailed in available sources). Like other serotonergic psychedelics, its hallucinogenic effects are presumed to be mediated primarily via 5-HT_2A agonism, potentially modulated by concurrent 5-HT_1A activity. Detailed binding affinity, selectivity, or functional data beyond these limited reports are currently scarce.

Subjective effects

This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠. Very limited anecdotal data exist. One published report described low sublingual doses (total ~6 mg, staggered) as producing effects qualitatively similar to 5-MeO-MiPT but milder, more clearheaded, somewhat tenser/crampier in body load, with reduced richness, empathy, appetite enhancement, and overall life-experience enhancement relative to 5-MeO-MiPT. Visual effects were minimal or absent at the doses tested. Potency appears roughly comparable to or slightly lower than 5-MeO-MiPT, though more data are needed.

Physical effects

• Limited reports mention mild body tension or cramping and a relatively clearheaded physical profile at low doses. Stimulation and tactile effects, if present, appear less pronounced than with related compounds such as 5-MeO-MiPT or 5-MeO-DiPT based on the available single-report comparison. Physical euphoria Spontaneous bodily sensations Muscle tension

Visual effects

• Visual effects appear minimal at low-to-moderate doses according to the limited available report.

  Enhancements

  • Colour enhancement (possible, mild)

  Distortions

  • Visual drifting (minimal or absent at low doses)

  Geometry

  Insufficient data.

  Hallucinatory states

  Insufficient data; closed- and open-eye visuals appear weak or absent at the low doses documented.

Cognitive effects

• Effects at low doses have been described as clearheaded with reduced empathogenic or mood-enhancing qualities compared to 5-MeO-MiPT. Analysis enhancement Thought acceleration Emotion enhancement (mild)

Auditory effects

• Insufficient data.

Multi-sensory effects

• Insufficient data.

Transpersonal effects

• Insufficient data.

Experience reports

There are currently 0 experience reports describing the effects of this substance in our experience index. You can also submit your own experience report using the same link.

Additional experience reports can be found here:

• Erowid Experience Vaults: 5-MeO-PiPT Reports

A small number of reports exist (primarily one detailed low-dose trial on Erowid). More data are required to characterize the effects profile reliably.

Toxicity and harm potential

This toxicity and harm potential section is a stub. As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational 5-MeO-PiPT use have not been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-PiPT is a research chemical with a very brief history of human use. Anecdotal evidence from people within the community who have tried 5-MeO-PiPT suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this substance.

Lethal dosage

The LD₅₀ of 5-MeO-PiPT has not been determined. As with other tryptamines, the risk of acute overdose appears relatively low when used in a controlled setting at moderate doses, but this has not been systematically studied.

Tolerance and addiction potential

As with most psychedelic tryptamines, 5-MeO-PiPT is not considered highly addictive. Tolerance is expected to develop with repeated use in a manner similar to related compounds, with cross-tolerance to other serotonergic psychedelics likely. Physical dependence or withdrawal symptoms have not been reported.

Dangerous interactions

This dangerous interactions section is a stub. As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit. 5-MeO-PiPT is expected to interact dangerously with other serotonergic agents (SSRIs, SNRIs, MAOIs, other psychedelics, certain opioids, etc.) due to the risk of serotonin syndrome. Combinations with stimulants, depressants, or other CNS-active substances should also be approached with extreme caution or avoided. No specific interaction data for 5-MeO-PiPT itself currently exist.

Legal status

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

5-MeO-PiPT is not explicitly scheduled under the United States Controlled Substances Act at the federal level. It may, however, be considered a controlled substance analogue of scheduled tryptamines (such as 5-MeO-DiPT) under the Federal Analogue Act if intended for human consumption. Legal status in other jurisdictions is largely unreported and may vary; it has appeared in designer-drug seizures in Canada.

See also

• Responsible use
• 5-MeO-MiPT
• 5-MeO-DiPT
• 5-MeO-DMT
• PiPT
• Tryptamine

External links

• 5-MeO-PiPT (Wikipedia)
• 5-MeO-PiPT (Erowid Experience Vaults)
• (Isomer Design / TiHKAL-related resources — check for related tryptamines)

Literature

Limited peer-reviewed literature exists. Primary sources are sparse analytical detections, patent literature mentioning the compound, and receptor pharmacology data embedded in broader 5-methoxytryptamine structure–activity studies.